Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation

Figure 1

Comparison among the levels of Ir-6-mediated inhibition of platelet aggregation induced by agonists in washed human platelets. (a) Synthesis of complex (Ir-6) [Ir(Cp)(L)Cl]BF₄. (b) Platelets (3.6 × 10⁸ cells/mL) were preincubated with the solvent control (0.1% DMSO) or Ir-6 (5–500 M) and subsequently treated with collagen (1 g/mL), arachidonic acid (AA; 120 M), thrombin (0.01 U/mL), or U46619 (1 M) to stimulate platelet aggregation. (c) Concentration–response histograms of Ir-6 representing the levels of inhibition of platelet aggregation stimulated by various agonists. Data are presented as the mean ± standard the error of the mean ().

(a)

(b)

(c)